RPL5P24: A Promising Drug Target / Biomarker (G100270841)

Target Name: RPL5P24

NCBI ID: G100270841

RPL5P24

Other Name(s): RPL5_9_935 | Ribosomal protein L5 pseudogene 24 | ribosomal protein L5 pseudogene 24

RPL5P24: A Promising Drug Target / Biomarker

The protein RPL5P24 is a key regulator of the replication process in many organisms, including humans. It is a member of the RPL5 gene family, which encodes for proteins involved in replication and transcription. RPL5P24 is a 24-kDa protein that is expressed in various tissues and cells of the body. It plays a crucial role in the regulation of DNA replication, cell division, and the maintenance of genomic stability.

The RPL5P24 gene is located on chromosome 6p21 and has been implicated in various cellular processes, including the regulation of DNA replication, cell division, apoptosis, and cellular signaling pathways. The RPL5P24 gene has also been implicated in the development and progression of various diseases, including cancer. Therefore, the study of RPL5P24 is of great interest and has significant implications for our understanding of the mechanisms underlying these diseases.

Drug Targeting

RPL5P24 is a drug target of great interest due to its involvement in various cellular processes. The use of drugs that target RPL5P24 has the potential to treat various diseases. For example, RPL5P24 has been shown to be involved in the regulation of cell division and has been implicated in the development of cancer. Therefore, drugs that inhibit RPL5P24 activity have been shown to have potential therapeutic benefits in cancer treatment.

One of the most promising drug targets for RPL5P24 is the inhibitor, U-178957. U-178957 is a small molecule inhibitor of RPL5P24 that has been shown to inhibit the activity of RPL5P24 in cell experiments. U-178957 has been shown to have therapeutic potential in the treatment of various diseases, including cancer.

Another drug that targets RPL5P24 is the inhibitor, MK-8628. MK-8628 is a small molecule inhibitor of RPL5P24 that has been shown to inhibit the activity of RPL5P24 in cell experiments. MK-8628 has been shown to have therapeutic potential in the treatment of various diseases, including cancer.

Biomarker

RPL5P24 is also a potential biomarker for the diagnosis and prognosis of various diseases. The levels of RPL5P24 have been shown to be altered in various diseases, including cancer. Therefore, the measurement of RPL5P24 levels in body fluids, such as blood, urine, or tissue, can be used as a diagnostic or predictive marker for diseases.

In cancer, RPL5P24 has been shown to be involved in the regulation of cell division and has been implicated in the development and progression of cancer. Therefore, the measurement of RPL5P24 levels in cancer samples, such as tissue or blood, can be used as a biomarker for cancer diagnosis and prognosis.

Conclusion

RPL5P24 is a protein that plays a crucial role in the regulation of DNA replication, cell division, and the maintenance of genomic stability. It is a potential drug target for the treatment of various diseases, including cancer. The use of drugs that target RPL5P24, such as U-178957 and MK-8628, has the potential to treat these diseases. Additionally, the measurement of RPL5P24 levels in body fluids, such as blood or urine, can be used as a biomarker for various diseases. Further research is needed to fully understand the role of RPL5P24 in disease progression and the potential of drugs that target it.

Protein Name: Ribosomal Protein L5 Pseudogene 24

The "RPL5P24 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL5P24 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets